Specifically, CDK4 amplification was linked to more aggressive tumor features—higher Breslow thickness, ulceration, mitotic rate, and clinical high-risk classification—as well as poorer MSS and DFS, underscoring its potential as a prognostic biomarker in ALM patients. This evidence concerns the gene CDK4 and acral lentiginous melanoma.